

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jinxin Fertility Group Limited

錦欣生殖醫療集團有限公司*

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 1951)

**VOLUNTARY ANNOUNCEMENT
KEY OPERATING DATA FOR THE NINE MONTHS ENDED
SEPTEMBER 30, 2025**

This is a voluntary announcement made by Jinxin Fertility Group Limited (the “**Company**”) to keep the shareholders of the Company and potential investors informed of the latest business developments of the Company and its subsidiaries (the “**Group**”).

The board of directors (the “**Board**”) of the Company is pleased to announce that, the Company has made solid progress in catching up of the number of in vitro fertilization (“**IVF**”) treatment cycles conducted for the nine months ended September 30, 2025. The Company remains highly confident in the long-term prospects of the industry and the Group’s growth, as underpinned by the Group’s solid industry foundation, continuous support from favorable national policies on the industry, as well as the Group’s ongoing efforts to enhance clinical treatment results, patient care and service offerings.

During the third quarter of 2025, driven by a series of management and operation improvement initiatives as well as a positive trend experienced in that period, the Group saw a slowdown in the decrease in the overall IVF treatment cycles from -8.3% (between the first half of 2024 and the first half of 2025) to a lesser -5.2% (between the first three quarters of 2024 and the first three quarters of 2025). Specifically, the number of IVF treatment cycles of the Group’s flagship hospital in Chengdu had caught up from -6.1% in the first half of 2025 to -1.9% for the nine month ended September 30, 2025, while the number of IVF treatment cycles in the Group’s Shenzhen hospital saw slower improvements compared to Chengdu due to preparations being made for the planned hospital relocation scheduled for the end of 2025. In the United States market, the postponement of the implementation of the California Senate Bill SB729 which requires commercial insurance coverage of assisted reproduction led to deferred IVF treatment cycles, so that the decline in the number of IVF treatment cycles under the Group’s United States operations is in line with its expectation.

The table below sets forth the number of IVF treatment cycles of the Group's in-network hospitals and by hospitals and clinics managed under invest-operate-transfer (“**IOT**”) agreements or management service agreements (“**MSA**”)¹ for the nine months ended September 30, 2025 with comparative figures for the nine months ended September 30, 2024:

Region	Number of IVF treatment cycles					
	For the nine months ended			For the six months ended		
	September 30, 2024	2025	Period-on- period changes	June 30, 2024	2025	Period-on- period changes
Chengdu	11,025	10,819	-1.9%	7,571	7,111	-6.1%
Greater Bay Area	4,473	3,869	-13.5%	3,022	2,539	-16.0%
Kunming and Wuhan	3,216	3,243	0.8%	2,133	2,059	-3.5%
Oversea (United States and Laos ^{Note})	3,481	3,104	-10.8%	2,325	2,099	-9.7%
Total	22,195	21,035	-5.2%	15,051	13,808	-8.3%

Note:

The Company has terminated its operations in Laos which is now undergoing necessary liquidation procedures.

The Company wishes to provide the shareholders and potential investors of the Company with a business update and the information contained herein is based on a preliminary assessment of the Group and the information currently available to the Company and is not based on any figure or information which has been audited or reviewed by the auditor of the Company. The above figures contained in this announcement are for illustrative purposes only, and do not constitute forward-looking statements or profit numbers.

Shareholders and potential investors of the Company are reminded to rationally deal with any information not officially released by the Company, and shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

By order of the Board
Jinxin Fertility Group Limited
Dong Yang
Chief Executive Officer,
Acting Chief Financial Officer and
Executive Director

Hong Kong, October 23, 2025

¹ *IOT/MSA institutions refer to hospitals and clinics controlled by the Group through discipline co-construction and cooperation agreements and management service agreements.*

As at the date of this announcement, the board of directors of the Company comprises Mr. Dong Yang, Ms. Lyu Rong and Dr. Geng Lihong, as executive Directors; Mr. Zhong Yong, as Chairman and non-executive Director, and Ms. Hu Zhe, Ms. Yan Xiaoqing and Mr. Chen Shuyun, as non-executive Directors; and Dr. Chong Yat Keung, Mr. Li Jianwei, Mr. Wang Xiaobo and Mr. Ye Changqing, as independent non-executive Directors.

** For identification purposes only*